Testing AccuracyEarly Phase 1NeWTS-DSNCT07813091
Controlled Oxygen Desaturation Study of the Neonatal Wireless Transmission System
A Early Phase 1 study testing Neonatal Wireless Transmission System in people with Testing Accuracy and Device Performance, run by Kathryn Beardsall at 1 site in United Kingdom.
Trial summary
This study aims to test the oxygen saturation component of the newly developed NeWTS monitoring system and compare readings from NeWTS to a traditional wired clinical monitor. It is important the investigators do this study in healthy adults as part of the development of this system, to make sure the oxygen saturation… Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Testing Accuracy, Device Performance
- What is being tested?
- Neonatal Wireless Transmission System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 11 Jan 2027to 31 Aug 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be aged 18-55 years
- Willing and have capacity to provide written informed consent
- Healthy adult volunteers classified as ASA 1
- Non-smoker (this does not exclude vaping)
- Willing and able to comply with study procedures and duration
Who cannot join
- History of Bleomycin treatment at any time
- Smokers or individuals exposed to high levels of carbon monoxide
- Compromised circulation, injury, or physical malfunction of the sensor sites which would limit the ability to test sites needed for the study
- Morbidly obese (defined as BMI >39.5) or significantly underweight (BMI <18)
- Pregnancy
- Participants who can conceive a pregnancy or carry a child (including women, trans men and non-binary people) will be required to demonstrate a negative pregnancy test
Show all 12Show fewer
- Unwillingness or inability to remove coloured nail polish or nail attachments from test digits (relevant for reference pulse oximeter) or to have medical monitoring attached
- Known health conditions or medications disclosed on Health Assessment Form which mean that participant is not healthy
- Allergy to lidocaine
- Known allergy to adhesives used in medical dressings or tapes or materials used to adhere NeWTS components.
- Enrolment in any other clinical investigation/trial that is deemed would compromise the validity of the data or safety of the patient (at the discretion of the local PI)
- Sunburn/spray tan or other pigments on hands
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Catherine Guy, BSc(Hons) contact
United Kingdom1 site
Clinical Research Facility
Birmingham, England, B15 2GW
Conor Jones, MSc, +447443264198, newts.hrcddr@uhb.nhs.uk
About this study
Official title: Controlled Oxygen Desaturation Study of the Neonatal Wireless Transmission System (NeWTS): NeWTS-DS
This study aims to test the oxygen saturation component of the newly developed NeWTS monitoring system and compare readings from NeWTS to a traditional wired clinical monitor. It is important the investigators do this study in healthy adults as part of the development of this system, to make sure the oxygen saturation readings are accurate and before NeWTS is used in Neonatal Intensive Care (NICU).
Read the detailed description
The aim of the controlled desaturation study is to show that the NeWTS device can safely measure blood oxygen content in comparison to the "gold-standard" method of measuring blood oxygen levels (SaO2). To assess this, blood oxygen levels will be measured while the amount of oxygen participants breathe is gradually reduced.
Healthy adults will start breathing oxygen at the same levels as in room air (21% oxygen) and this will be gradually reduced. The measurements from the NeWTS device will be compared to the value taken directly from the blood via an arterial line (SaO2). The SaO2 is measured by obtaining multiple blood samples from an artery in the body.
As described in EN ISO 80601-2-61:2026 a minimum of 24 participants will be recruited with an average of 20 (±4), range 16-30 data points per participant.
The investigators will include a distribution of data pairs, with total pairs split across each desaturation decade between 70 % to 100 % saturations, with approximately 33 %, but no less than 25 %, in each decade.
90 % or greater of participants shall provide at least one useable data pair with an SaO2 below 85 %.
At least 75 % of participants shall also have provided at least one useable data pair with an SaO2 between 70 % to 80 %.
The number of data pairs for a given SaO2 decile (i.e. 70 % to 80 %, 80 % to 90 % and 90 % to 100 %) will be derived approximately equally from participants across skin pigment categories, ensuring that >25 % of data points come from light, medium and dark participants by MST and ITA.
- Conditions
- Testing Accuracy, Device Performance
- Being tested
- Neonatal Wireless Transmission System
- Keywords
- Neonatal Wireless Transmission System (NeWTS), Controlled oxygen desaturation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neonatal Wireless Transmission SystemDevice
The primary objective for this clinical investigation is to validate the SpO2 performance of the NeWTS in comparison to "gold-standard" measurements of blood SaO2 by a calibrated and QC'ed ABL90 Flex plus blood gas analyser.
| Study group | Role | What they receive |
|---|---|---|
| Controlled Oxygen Desaturation of Healthy Adult Volunteers | Other | Not described Receives: Device: Neonatal Wireless Transmission System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Validation of SpO2 performance
Validation of the SpO2 performance of the NeWTS in comparison to "gold standard" measurements of blood SaO2 by a calibrated and QC'ed ABL90 Flex plus blood gas analyser.
Measured: From enrolment to end of study 3-4 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study start11 Jan 2027 (estimated)
- Primary completion4 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Testing AccuracyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kathryn Beardsall
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University of Cambridge, University Hospital Birmingham NHS Foundation Trust
- Responsible party
- Sponsor-investigator, Kathryn Beardsall, Cambridge University Hospitals NHS Foundation Trust
- Investigators
- Kathryn Beardsall, MD, Principal investigator, University of Cambridge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07813091
- Sponsor's protocol ID
- A097812
- Other IDs
- NIHR206500
- Acronym
- NeWTS-DS
- Status last verified
- Aug 2026
- First submitted
- 27 Aug 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Controlled Oxygen Desaturation Study of the Neonatal Wireless Transmission System (NeWTS): NeWTS-DS
- ClinicalTrials.gov ID
- NCT07813091
- Acronym / sponsor ID
- NeWTS-DS / A097812
- Conditions
- Testing Accuracy, Device Performance
- Keywords
- Neonatal Wireless Transmission System (NeWTS), Controlled oxygen desaturation
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Kathryn BeardsallUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University of Cambridge, University Hospital Birmingham NHS Foundation Trust
- Study start
- 11 Jan 2027 (estimated)
- Primary completion
- 4 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to test the oxygen saturation component of the newly developed NeWTS monitoring system and compare readings from NeWTS to a traditional wired clinical monitor. It is important the investigators do this study in healthy adults as part of the development of this system, to make sure the oxygen saturation readings are accurate and before NeWTS is used in Neonatal Intensive Care (NICU).
Detailed description
The aim of the controlled desaturation study is to show that the NeWTS device can safely measure blood oxygen content in comparison to the "gold-standard" method of measuring blood oxygen levels (SaO2). To assess this, blood oxygen levels will be measured while the amount of oxygen participants breathe is gradually reduced.
Healthy adults will start breathing oxygen at the same levels as in room air (21% oxygen) and this will be gradually reduced. The measurements from the NeWTS device will be compared to the value taken directly from the blood via an arterial line (SaO2). The SaO2 is measured by obtaining multiple blood samples from an artery in the body.
As described in EN ISO 80601-2-61:2026 a minimum of 24 participants will be recruited with an average of 20 (±4), range 16-30 data points per participant.
The investigators will include a distribution of data pairs, with total pairs split across each desaturation decade between 70 % to 100 % saturations, with approximately 33 %, but no less than 25 %, in each decade.
90 % or greater of participants shall provide at least one useable data pair with an SaO2 below 85 %.
At least 75 % of participants shall also have provided at least one useable data pair with an SaO2 between 70 % to 80 %.
The number of data pairs for a given SaO2 decile (i.e. 70 % to 80 %, 80 % to 90 % and 90 % to 100 %) will be derived approximately equally from participants across skin pigment categories, ensuring that >25 % of data points come from light, medium and dark participants by MST and ITA.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Controlled Oxygen Desaturation of Healthy Adult Volunteers | Other | Device: Neonatal Wireless Transmission System |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Be aged 18-55 years
Key exclusion criteria (12 listed)
- History of Bleomycin treatment at any time
- Smokers or individuals exposed to high levels of carbon monoxide
- Compromised circulation, injury, or physical malfunction of the sensor sites which would limit the ability to test sites needed for the study
- Morbidly obese (defined as BMI >39.5) or significantly underweight (BMI <18)
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neonatal Wireless Transmission SystemThe primary objective for this clinical investigation is to validate the SpO2 performance of the NeWTS in comparison to "gold-standard" measurements of blood SaO2 by a calibrated and QC'ed ABL90 Flex plus blood gas analyser. | Device | Controlled Oxygen Desaturation of Healthy Adult Volunteers |
Primary outcome
Validation of SpO2 performance
Time frame: From enrolment to end of study 3-4 hours
Validation of the SpO2 performance of the NeWTS in comparison to "gold standard" measurements of blood SaO2 by a calibrated and QC'ed ABL90 Flex plus blood gas analyser.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
Related trials for Testing Accuracy
RecruitingObservational study
Artificial Intelligence, Obstetricians, and Midwives in Non-Stress Test Interpretation
Non-Stress Test Interpretation, Fetal Well-Being Assessment
Not yet recruitingObservational study
Fluid Responsiveness in Laparoscopic Surgery: End-Expiratory Occlusion Test Versus Mini-Fluid Challenge
Fluid Responsiveness, Laparoscopic Surgery
Enrolling by invitationObservational study
Comparing an AI-driven Hearing Test With the Standard Hearing Test in Adults With Hearing Loss and Tinnitus
Sensorineural Hearing Loss, Tinnitus
Enrolling by invitationObservational study
Evaluating the Accuracy of Multiple Blood Tests to Diagnose Sepsis in Adult Burn Patients
Sepsis - to Reduce Mortality in the Intensive Care Unit, Burns Involving 20% or More of Body Surface
RecruitingObservational study
A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD
Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Catherine Guy, BSc(Hons) contact
Kathryn Beardsall, MD principal investigator
University of Cambridge
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Neonatal Wireless Transmission System in people with Testing Accuracy and Device Performance, run by Kathryn Beardsall at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kathryn Beardsall, MD (+447565 964631, kb274@cam.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validation of SpO2 performance (time frame: From enrolment to end of study 3-4 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.